David Hung, Nuvation Bio CEO
August 5, 2024 03:35 PM EDT
R&D

Nu­va­tion paus­es BET in­hibitor plans af­ter check­ing out in­ter­im Phase 1 da­ta

Max Bayer

Pharma Reporter

Nu­va­tion Bio won’t take its can­cer drug NUV-868 in­to a Phase 2 tri­al for now, fol­low­ing a look at in­ter­im safe­ty and ef­fi­ca­cy da­ta from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times